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Functional bowel disorders 
are more common in women 
than men
They become less common
after mid-life 
Pie chart:
% of adults with 
each disorderAbbreviations used in this paper: CI, confidence interval; FBD, functional
bowel disorder; FC, functional constipation; GI, gastrointestinal; IBS, irri-
table bowel syndrome; IBS-C, IBS with predominant constipation; IBS-D,
IBS with predominant diarrhea; IBS-M, IBS with mixed bowel habits; IBS-
U, IBS unclassified; OIC, opioid-induced constipation; OR, odds ratio; SF-
8, Short Form 8.BACKGROUND & AIMS: Little is known about the population
prevalence or demographic distributions of Rome IV functional
bowel disorders (FBDs) or their effects on quality of life. We
examined these in a multinational survey. METHODS: We
analyzed data from a population-based survey of adults in the
United States, Canada, and United Kingdom (5931 valid re-
sponders; 49.2% female; mean age, 47.4 years; range, 18–92
years). The survey included the Rome IV Diagnostic Question-
naire, Rome III irritable bowel syndrome (IBS) and constipation
questions, and the SF-8 quality of life questionnaire. RESULTS:
The prevalence values of census-adjusted Rome IV FBDs were
similar among the 3 countries; ranges were: 4.4%–4.8% for IBS,
7.9%–8.6% for functional constipation, 3.6%–5.3% for func-
tional diarrhea, 2.0%–3.9% for functional bloating or disten-
tion, 1.1%–1.9% for opioid-induced constipation, 7.5%–10.0%
for unspecified FBDs, and 28.6%–31.7% for any Rome IV FBD.
FBDs were less common in older individuals, and all except
functional diarrhea were more common in women. IBS was
only half as prevalent by Rome IV as by Rome III criteria (4.6%
vs 9.0% overall), primarily due to higher Rome IV minimum
pain frequency. Functional diarrhea and functional constipation
were more prevalent by Rome IV than Rome III criteria. Sub-
jects with FBD had significant reductions in quality of life and
reported more gastrointestinal doctor consultations than othersubjects. CONCLUSIONS: More than 1 in 4 adults in the general
population meet the Rome IV criteria for FBDs. These disorders
affect quality of life and increase use of gastrointestinal health
care. The switch from Rome III to Rome IV criteria reduces the
prevalence of IBS by half, but increases the prevalence of
functional constipation and functional diarrhea.Keywords: Abdominal Pain; Epidemiology; Europe; GI Disorder.
he functional bowel disorders (FBDs) are a subset ofTa larger family of functional gastrointestinal (GI)
disorders (FGIDs),1 and involve chronic symptoms of
abdominal pain, bloating, diarrhea, and constipation in the
lower half of the GI tract. Like other FGID, the FBDs have no
identifiable structural or biochemical abnormalities that can
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
Little is known about the population prevalence or
demographic distributions of Rome IV functional bowel
disorders (FBDs) or their effects on quality of life
NEW FINDINGS
More than 25% of adults in the general population meet
the Rome IV criteria for FBDs. These disorders affect
quality of life and increase use of gastrointestinal
healthcare.
LIMITATIONS
This is a study of the populations of 3 countries. Studies
of other populations are needed.
IMPACT
The switch from Rome III to Rome IV criteria reduces the
prevalence of IBS by half, but increases the prevalence of
functional constipation and functional diarrheaaccount for their defining symptoms. Diagnosis therefore
relies almost exclusively on symptom patterns, and the
Rome diagnostic criteria are the most widely accepted
standard for such symptom-based diagnoses. The latest
version of those criteria, Rome IV, recognizes 6 different
FBDs.2 Five of these were also in the Rome III classification
system: irritable bowel syndrome (IBS), functional con-
stipation (FC), functional diarrhea, functional abdominal
bloating/distention, and unspecified bowel disorder. The
sixth disorder, introduced for the first time in Rome IV, is
opioid-induced constipation (OIC), which differs from all the
other FBDs in that it has an identifiable organic cause, that
is, opioid use.3
Apart from the addition of OIC, the only notable changes
between Rome III and IV definitions of FBDs were in the
criteria for IBS and functional diarrhea. IBS diagnosis
changed from Rome III to Rome IV in 3main aspects4: (1) the
qualifying symptom of “abdominal discomfort or pain” was
modified to just “abdominal pain”; (2) the minimum
abdominal pain frequency required for diagnosis was
increased from 2 to 3 days a month to once a week; and (3)
rather than tying stool consistency abnormality to pain onset
as in Rome III, Rome IV diagnosis only requires association of
pain with defecation or changes in stools. In addition, IBS
subtypes are defined in Rome IV based on the typical type of
stool consistency abnormality (diarrhea, constipation, or a
mix) on days in which such abnormal stools occur, rather
than on proportions of different kinds of abnormal stools out
of all bowel movements as in Rome III. Rome III functional
diarrhea diagnosis required at least 75% of bowel move-
ments in the past 3 months to be loose or watery in a person
with no abdominal pain or discomfort. Rome IV criteria for
this disorder are far more permissive, requiring only >25%
of stools to be loose or watery in the past 3 months in in-
dividuals who do not meet IBS criteria and do not have
predominant symptoms of abdominal pain or bloating.
The prevalence of FBDs in the general population has
remained unclear in spite of considerable research on theirepidemiology. The principal reasons for this are that defini-
tions of the disorders, survey methodologies, and the pop-
ulations studied in the published research have varied greatly,
resulting in very divergent and hard-to-compare findings.5 In
addition, the research focus has mainly been on only 2 of the
bowel disorders, IBS and FC, with far less prevalence research
published on the others. A 2012 systematic review by Lovell
and Ford6 of 81 studies of IBS, conducted in numerous coun-
tries and using a number of different criteria, concluded that
the pooled global prevalence of the disorder was 11.2%, with
prevalence reports ranging all the way from 1.1% to 45.0%.
For FC, a 2011 systematic review by Suares and Ford7 found a
pooled prevalence of 14% in 41 study populations, with
similarly extreme spread of prevalence, ranging from 1.9% to
40.1%. Little can be concluded about population prevalence
rates from such a broad set of estimates based on multiple
disorder definitions and sampling methods.
Practically no information is available in the literature
that provides a comprehensive picture of the FBDs as a class
in national populations. These disorders are a set of over-
lapping and interactive symptoms, and it is well recognized,
as emphasized by the Rome IV bowel disorders working
team,2 that they often transition over time in the same in-
dividual. Therefore, examining their collective presence in
the population as a group gives a better idea of functional
health problems in the lower GI tract than merely focusing
on individual diagnoses.
The heterogeneity of methodologies and case definitions
in past work has made it hard to know whether the FBDs
generally afflict different demographic groups at different
rates. However, there has been a fairly consistent indication
from multiple studies that IBS and FC tend to occur at
higher rates in female than in male individuals, and that
constipation is more prevalent in older than in younger
adults, whereas IBS declines in prevalence in the upper half
of the adult age range.6–8 Finally, no national prevalence
estimates for Rome IV bowel disorders in adults exist yet in
the published literature, with the exception of a single es-
timate for IBS in Belgium,9 making the provision of such
data much needed to understand the scope of these health
problems as they are presently defined.
The aims of this report were to describe and compare
the prevalence of the Rome IV bowel disorders in the adult
populations of 3 English-speaking Western countries,
examine how the change from Rome III to Rome IV criteria
affected the prevalence of 3 of these disorders (IBS, FC, and
functional diarrhea), and assess differences in FGID preva-
lence between demographic subgroups and the quality of
life impact of these disorders.
Materials and Methods
The analyses in this report used data from a population-
based survey of 6300 adults commissioned by the Rome
Foundation in the fall of 2015 as a part of the validation process
for the forthcoming Rome IV diagnostic criteria.10 The survey
was conducted online, using Qualtrics Research Suite survey
software (Qualtrics, LLC, Provo, UT). All survey participants
were provided by Qualtrics, LLC, an international survey
1. To avoid self-selection bias, the survey was described
only as a health survey to prospective subjects, without
any mention of GI symptoms or disorders.
2. The survey was a secure, closed survey accessible only to the
registered survey panel members specifically invited to
participate basedon their knowndemographic characteristics.
3. Twomultiple-choice attention-test questions were built into
the survey. These looked like other questions but specifically
asked subjects to enter a particular response. Subjects who
failed to respond appropriately to either question were
terminated from the survey without completion.
4. Respondents who answered questions at more than 3
times the median completion speed (as determined by
the first 10% of the sample) were excluded from the
dataset.
5. Three Rome IV diagnostic questions were repeated later
in the survey to assess symptom reporting consistency.
Data from subjects who failed to report comparable
symptom frequency on 2 or more of these 3 repeated
questions were eliminated from the analysis dataset.
company, from existing panels of individuals who had already 
enrolled in registries to participate in various online surveys. 
Survey participants were kept anonymous to the investigators.
Nationwide community samples of 2100 individual age 18 
years and older were recruited in the United States, United 
Kingdom, and Canada. The sampling was quota-controlled to 
obtain an equal proportion of male and female individuals, an 
age group distribution of 40% of ages 18 to 39, 40% ages 40 to 
64, and 20% aged 65þ in each country, and a 30% maximum 
quota of individuals with education equivalent to a college 
degree (16 years of schooling or greater).
Subjects first completed online consent, and then proceeded 
to complete the study survey right away. The survey questions 
used in the analyses in this report included the Rome IV 
Diagnostic Questionnaire for Adult Functional Gastrointestinal 
Disorders,10 the Rome III IBS and FC diagnostic modules,4 de-
mographic questions (age, sex, education, relationship status, 
population size, and region of residence within each country), 
the Short Form 8 (SF-8) quality of life questionnaire,11 and 
questions on GI health history and doctor consultations for GI 
problems. The survey also contained other supplemental 
questions and questionnaires not used in the present analyses.
Several methods were used to ensure good quality of the 
data collected:Identification of Rome IV and Rome III FGID
Cases
Likely organic causes of bowel symptoms should generally
be ruled out before making Rome functional GI diagnoses. For
this reason, we chose to exclude from Rome FBD diagnoses in
our analyses all subjects in the survey sample who reported
having been diagnosed with any of 5 self-reported organic
health problems that were likely to affect or cause bowel
symptoms: celiac disease, inflammatory bowel disease, GI
cancer, peptic ulcer, and diverticulitis. We also excluded from
FBD diagnoses individuals who reported having had a bowel
resection. After these exclusions, we identified FGID casesaccording to the Rome scoring instructions and Rome IV and
Rome III diagnostic criteria, as summarized in Table 1.
The study was reviewed by the institutional review board at
the University of North Carolina at Chapel Hill before data
collection started and was deemed institutional review board
exempt because of the anonymity of the survey method.
Statistical Analysis
The data were analyzed with IBM SPSS Statistics version
25.0 software (IBM Corp., Armonk, NY).
Descriptive statistics using means with 95% confidence
intervals were used to characterize the rates of the disorders
investigated in the overall sample, within each country, and in
demographic subgroups.
Chi-square tests of independence were used for comparisons
of proportions of individualswith the different bowel disorders in
demographic subgroups and between countries, as well as for
comparing Rome III vs Rome IV prevalence rates. Odds ratioswith
95% confidence intervals were calculated for select comparisons
to describe relative risk of FBDs in subgroups.
Analysis of variance with post hoc significance tests using
Bonferroni correction for multiple comparisons were used to
compare diagnostic groups on continuous variables.
The latest national government census figures in each of the
3 countries12–14 were used to calculate correction weights for
age (in 5-year bins) and sex proportions, to make the age
and sex distributions of the survey samples proportionally
equivalent to those of the national populations. These
population-weighted sample data were used to produce overall
census-adjusted prevalence estimates for the FBDs in each
country as well as overall for the 3 countries combined.Results
Survey Sample Characteristics
The study survey was completed by a total of 6300 in-
dividuals (2100 in each of the 3 countries). A total of 369
subjects judged to be inconsistent responders based on the 3
repeated Rome IV diagnostic questions were eliminated from
the dataset. As seen in Supplementary Table 1, these incon-
sistent responders were on average younger, more likely to
be female and slightly less educated than other survey re-
sponders. Their elimination left 5931 valid response sets for
analysis (94% of the original sample). Due to quota-based
sampling, there were no significant differences between the
country samples in age group distributions or sex ratios.
Overall, the combined total sample was 49.2%women, with a
mean age of 47.4 years (range 18–92 years), and 72.0%white
race. Subject participation was nationwide in each country,
with the proportion of participants in different parts of their
respective countries generally similar to the proportions of
the national population living in those states (US), govern-
ment regions (UK), or province and territories (Canada).
Further details of the study sample demographics can be
found in a previous publication using this sample,15 and in
Supplementary Tables 2–8.
A total of 230 subjects in the study sample (3.9%) who re-
ported 1 or more of the 6 exclusion conditions that might ac-
count for their bowel symptoms but otherwise met criteria for
Table 1.Criteria Used to Identify Rome III and Rome IV FBD Cases in the Study
Rome IV IBS Required abdominal pain at least weekly in the past 3 months, which also met 2 of the following conditions: was
temporally related to defecation, associated with change in stool frequency, or associated with change in stool
consistency.
Rome IV IBS subtyping was based on responses to a single question about the usual type of stool abnormality on days
when diarrhea or constipation are present, with the Bristol Stool Form Scale for reference. The 4 response options,
each of which lead to classification as 1 of the 4 IBS subtypes if selected by the respondent, were “Usually
constipation (like Type 1 or 2 in the picture),” “Usually diarrhea (like Type 6 or 7),” “Both diarrhea and constipation,
that is, more than 1/4 of all the abnormal bowel movements were constipation and more than 1/4 were diarrhea,” and
“Not applicable, because I never or rarely had abnormal bowel movements.”
Rome III IBS Required abdominal discomfort or pain at least 2 to 3 days a month in the past 3 months that was at least on some
occasions associated with 2 or more of the following: improvement after defecation, change in stool frequency, or
harder or looser stools.
Rome III subtyping depended on responses to diagnostic questions about frequency of hard or loose stools. Individuals
reporting having hard/lumpy stools or loose/watery stools at least “Sometimes” (assumed in Rome III to equate 25%
or greater frequency) without the opposite stool abnormality meeting that frequency threshold were classified as IBS-
C or IBS-D, respectively. If hard/lumpy stools and soft/watery stools were both sometimes present, patients were
subtyped as IBS-M, but as IBS-U if none of the other 3 subtype definitions were met.
Rome IV FC Required presence of at least 2 of 6 constipation symptoms at a minimum frequency of 25% of all stools: lumpy or
hard stools, sensation of incomplete evacuation, sensation of anorectal obstruction or blockage during defecation,
infrequent defecation (fewer than 3 times per week), straining, or need for manual maneuvers to facilitate defecation.
The minimum frequency for each symptom was approximated by using a 30% or greater as qualifying, as the closest
10% increment in the Rome IV response scale for FC symptoms meeting the threshold. The exception was
infrequent defecation, for which a threshold of >50% of weeks was used. FC was diagnosed only if the individual did
not fulfill criteria for IBS or OIC and diarrhea occurred no more than rarely without laxatives.
Rome III FC Required the same symptom criteria as for Rome IV: 2 of the 6 constipation symptoms listed for Rome IV FC above
being met at 25% frequency threshold. However, the response scale in the Rome III diagnostic questionnaire is
simply a 5-point scale of “Never or rarely,” “Sometimes,” “Often,” “Most of the time,” and “Always.” The minimum
threshold was therefore set for each symptom as recommended in the standard Rome III diagnostic scoring: at least
“Sometimes” for sensation of incomplete evacuation, sensation of blockage during defecation, and need for manual
maneuvers to defecate, but at least “Often” for hard/lumpy stools, infrequent defecation, and straining. Furthermore,
for diagnosis of Rome III FC, diarrhea must not be present more than rarely and IBS criteria must not be met.
Rome IV Functional
Diarrhea
Required at least 30% of all stools (the closest approximation to >25% on the 10% increment frequency response
scale) to be of Bristol Type 6 or 7 in the past 3 months, IBS criteria not to be met, and abdominal pain or bloating to
not be predominant symptoms.
Rome III Functional
Diarrhea
Required loose or watery stools on at least 75% of bowel movements in the past 3 months in the absence of abdominal
discomfort or pain. As the exact Rome III questions to diagnose this disorder were not included in the survey, survey
respondents were qualified for the diagnoses if 80% or more of their total bowel movements (the closest
approximation to 75% on the 10% Rome IV increment frequency response scale) in the past 3 months were of
Bristol Stool Form Type 6 or 7, and they also responded “Never” to the included Rome III question on frequency of





Required symptoms of bloating and/or distention occurring at least weekly and reported to be the predominant
symptoms in the past 3 months, in individuals not meeting diagnostic criteria for IBS, functional diarrhea, FC, or post-
prandial distress syndrome.
Rome IV OIC Required constipation symptoms equivalent to those defining Rome IV FC over the past 3 months, but where those
symptoms were reported to have started or worsened in relation to beginning of, change in, or increase in, use of




Required 1 or more of the key symptoms of the other FBDs (abdominal pain, bloating/distention, constipation, or
diarrhea) to be present at the minimum diagnostic frequency threshold for those other disorders in the past 3 months,
but criteria not met for diagnosis of any of the specific bowel disorders.
NOTE.All diagnoses also required the symptoms to have been present for 6 months.FBD diagnosis were excluded from those diagnoses and were
not counted as FBD cases in the analyses presented as follows.
Prevalence of FBDs
In the combined 3-nation study sample, 27.8% of all
survey respondents (n ¼ 1650) met criteria for a Rome IV
FBD diagnosis. There was no difference between countries
in this overall FBD rate (see Table 2). Women had a
significantly higher prevalence of FBDs than men in each of
the 3 countries as well as in the total sample, with an oddsratio (OR) of 2.0 (95% confidence interval 1.8–2.2) in the
combined sample. Individuals older than 50 had signifi-
cantly lower prevalence of FBDs compared with younger
people, and the prevalence was lowest among individuals
65 and older (Table 3).
Irritable bowel syndrome. The Rome IV IBS preva-
lence was 4.6% in the whole study sample. The rate was
practically identical in the 3 countries (Table 2), ranging
from 4.5% in Canada to 4.7% in the United States. The Rome
III IBS rate was approximately twice as high as the Rome IV












IBS 4.6 (4.1–5.2) 4.7 (3.8–5.7) 4.5 (3.6–5.4) 4.6 (3.7–5.5) .96
FCb 7.8 (7.1–8.5) 6.9 (5.8–8.0) 7.9 (6.7–9.1) 8.6 (7.4–9.9) .12
Functional diarrhea 4.7 (4.2–5.3) 4.9 (3.9–5.8) 5.6 (4.6–6.6) 3.8c (2.9–4.6) .02
Functional bloating/distention 3.1 (2.7–3.6) 2.2c (1.5–2.8) 3.9 (3.0–4.7) 3.3 (2.5–4.1) .007
OIC 1.5 (1.2–1.9) 1.7 (1.2–2.3) 1.0d (0.5–1.4) 1.9 (1.3–2.5) .03
Unspecified bowel disorder 9.1 (8.4–9.9) 9.9 (8.6–11.2) 10.1 (8.7–11.4) 7.5d (6.3–8.6) .007
Any bowel disorder 30.1 (29.0–31.3) 29.5 (27.5–31.5) 31.9 (29.9–34.0) 28.9 (26.9–30.9) .09
Rome III
IBS 9.0 (8.2–9.7) 8.6 (7.3–9.8) 9.5 (8.2–10.8) 8.8 (7.5–10.0) .56
FC 5.6 (5.0–6.2) 4.9 (3.9–5.8) 5.0 (4.1–6.0) 6.8e (5.7–7.9) .02
Functional diarrhea 0.9 (0.6–1.1) 0.9 (0.5–1.3) 1.0 (0.5–1.5) 0.7 (0.3–1.1) .58
NOTE. (95% CI in parentheses)
aP values indicating significant differences are identified by bold type.
bThe prevalence values for FC presented here and elsewhere in this article are obtained with scoring in accordance with the
published Rome IV diagnostic criteria. If the stricter research diagnostic scoring suggested in the Rome IV book (Rome IV
Functional Gastrointestinal Disorders: Disorders of Gut-Brain Interaction, Volume 2. Rome Foundation: Raleigh, NC. Page
1552) is used, FC rates are lower: 5.7% for the overall sample, 5.1% for the United States, 5.2% for Canada, and 6.7% for the
United Kingdom.
cSignificantly lower prevalence than in Canada.
dSignificantly lower than in both the other countries.
eSignificantly higher prevalence than in both the other countries.rate: It was 9.0% in the total 3-country sample, ranging
from 8.6% in the United States to 9.5% in Canada, with no
significant difference between countries.
In all 3 countries sampled, andby both versions of theRome
criteria, IBS rate was significantly higher in women than men,
except for Rome IV IBS in the United States, where it did not
reach statistical significance (P¼ .07). The female/male OR for
having IBS was 1.9 (1.5–2.5) for Rome IV IBS and 2.3 (1.9–2.7)
for Rome III IBS in the total study sample. Both Rome IV and
Rome III IBS rates had significantly lower prevalence among
individuals aged 65 years or older comparedwith younger age
groups (see Table 3), and this was also true for each of the 3
countries when their data were analyzed separately.
There were no significant differences between countries
in the distributions of IBS subtypes among individuals
qualifying for IBS diagnosis (Figure 1); however, the dis-
tribution of IBS subtypes was substantially different be-
tween the 2 versions of the Rome criteria (P < .0001). When
Rome IV criteria were applied, IBS with predominant con-
stipation (IBS-C), IBS with predominant diarrhea (IBS-D),
and IBS with mixed bowel habits (IBS-M) all constituted
similar-sized and substantial proportions of the IBS cases,
whereas only 4.4% to 6.5% of them had IBS unclassified
(IBS-U). In contrast, IBS-M accounted for a far larger portion
of all IBS cases than any of the other subtypes in Rome III
subtyping, representing more than half of the cases (see
Figure 1). IBS-U was very uncommon in Rome III as in Rome
IV, amounting for only 1.2% to 4.6% of all IBS cases.
The substantially lower percentage of individuals
meeting Rome IV IBS criteria compared with Rome III
criteria, a drop by approximately half, led us to conduct
follow-up analyses to examine how the specific changes inthe criteria had produced this large decrease in individuals
qualifying for IBS diagnosis. As described previously, 3 main
changes were made in IBS diagnosis in Rome IV compared
with the Rome III criteria: elimination of the word
discomfort from the question about abdominal pain,
changes in criteria about the relationship of pain and stools,
and increase in minimum frequency of pain to once a week.
With our advantage of having answers from the same in-
dividuals to both the Rome III and Rome IV diagnostic IBS
questions in the dataset, we were able to examine the
impact of each of these changes independently, by altering 1
criterion at a time in the diagnostic algorithm but keeping
everything else unchanged, and calculating the effects of this
on diagnostic rates.
Starting with the 723 nonorganic cases who met the
Rome III minimum pain/discomfort frequency threshold of
2 to 3 times a month (and who reported having had this
symptom for 6 months), we first examined the difference in
numbers of people meeting or exceeding that frequency
threshold when asked instead about frequency of abdominal
pain only (ie, the Rome IV question). We discovered that 62
fewer individuals reported abdominal pain on the Rome IV
diagnostic question at the minimum frequency threshold of
2 to 3 days a month, compared with the numbers obtained
using the Rome III question. This quantified the impact of
dropping discomfort from the pain threshold question, in
isolation from other changes made in the diagnostic criteria.
Using the remaining 661 individuals who reported
abdominal pain on the Rome IV question at a frequency of 2
to 3 times a month or more, we next evaluated the size of
the impact of raising the minimum frequency of abdominal
pain to once a week. We found that 296 fewer people
Table 3.Percent Prevalence of Functional Bowel Disorders in Sex and Age Groups in the Combined Three-Country Population
















6.1 (5.2-6.9) 3.2 (2.6-3.9) <.0001 5.0 (3.9-6.0) 6.4 (5.1-7.7) 5.0 (3.9-6.1) 1.7a (1.0-2.4) <.0001
Functional
constipation
10.1 (9.1-11.2) 5.5 (4.7-6.4) <.0001 9.9d (8.5-11.4) 8.0 (6.6-9.4) 6.4 (5.2-7.6) 6.5 (5.1-7.9) <.0002
Functional diarrhea 5.1 (4.3-5.9) 4.4 (3.7-5.1) .11 4.1 (3.2-5.1) 6.0e (4.8-7.3) 5.1 (4.0-6.1) 3.8 (2.7-4.8) .03
Functional bloating/
distention
4.6 (3.8-5.4) 1.7 (1.2-2.12) <.0001 3.6 (2.7-4.5) 3.6 (2.6-4.6) 3.2 (2.3-4.0) 1.9a (1.1-2.6) .04
Opioid-induced
constipation





8.3 (7.3-9.3) <.001 11.3g (9.8-12.8) 8.6 (7.2-10.1) 8.6 (7.2-9.9) 7.4 (6.0-8.9) <.002
















12.2 (11.0-13.4) 5.8 (5.0-6.6) <.0001 9.6 (8.2-11.0) 11.2 (9.5-12-9) 9.4 (8.0-10.8) 5.0a (3.8-6.2) <.0001
Functional constipation 7.3 (6.4-8.3) 3.9 (3.2-4.5) <.0001 5.4 (4.3-6.5) 6.4 (5.1-7.8) 5.2 (4.2-6.3) 5.2 (4.0-6.5) .44
Functional diarrhea 0.8 (0.2-1.3) 0.6 (0.1-1.1) .43 0.5 (0.0-1.1) 0.2 (-0.2-0.6) 1.5 (0.5-2.5) 0.5 (-0.2-1.2 ) .07
NOTE. (95% CI in Parentheses).
aSignificantly lower prevalence than in all the other age groups.
bSignificantly lower than age group 18-34.
cSignificantly lower than age group 35-49.
dSignificantly higher prevalence than the two oldest age groups.
eSignificantly higher prevalence than in age groups 18-34 and 65+.
fSignificantly higher prevalence than in age groups 18-34 and 65+.
gSignificantly higher prevalence than in all the other age groups.
hP-values indicating significant differences are identified by bold type.endorsed abdominal pain at least weekly, eliminating 40.9%
of all the individuals who met a minimum threshold for pain
at 2 to 3 times a month.
Finally, we compared the effects of changes made in Rome
IV in questions about associations with bowel functioning on
qualification for diagnosis among the 365 individuals still
potentiallyqualifying for IBSdiagnosisaftermeeting theweekly
pain requirement. This revealed that very similar numbers
qualified for Rome IV IBS regardless of whether we applied
their Rome III or Rome IV responses to questions on the rela-
tionship of stools and pain. Only 9 fewer individuals qualified
for diagnosis on this basis when Rome IV questions were used
to determine eligibility for diagnosis, indicating that the change
inwording inRome IV IBS on those questions, such asdropping
the association with relief of pain after bowel movement, has
minimal effect on diagnostic rate.
In summary, our analysis found, by examining each of
the 3 changes made in the Rome criteria for IBS by Rome IV
separately and sequentially, that most of the relative
reduction in diagnostic rate, or 80.7% (296/[62þ296þ9]),
is accounted for by just 1 of those changes;:the increase of
the minimum pain frequency threshold from 2 to 3 days a
month to once a week. This is illustrated in Figure 2.
The large reduction in IBS diagnosis rate with Rome IV
criteria compared with Rome III invites the question of whathappens in the Rome IV diagnostic classification system to the
approximately half of individuals who would receive IBS diag-
nosis in Rome III but are disqualified from it in Rome IV. A
detailed answer to that question is provided in the pie graph in
Figure2. As shown there, fewer thanone-third (28.7%)of those
individuals do not qualify for any bowel disorder diagnosis in
the Rome IV classification system, whereas more than two-
thirds meet diagnostic criteria for 1 of the other 5 FBDs.
Functional constipation. Rome IV FC had a preva-
lence of 7.6% in the overall study sample. The 3 countries
had equivalent constipation rates, ranging from 6.9% in the
United States to 8.6% in the United Kingdom, although the
UK prevalence showed a trend toward being higher than in
the United States (Table 2).
The Rome III constipation prevalence in the overall study
sample, although diagnosed based the same 6 symptoms as in
Rome IV (see Table 1), was significantly lower than Rome IV
prevalence, or 5.6%. The prevalencewas significantly higher in
the United Kingdom compared with the other 2 countries.
Women were more likely to have a diagnosis of FC than
men in all countries and with both versions of the Rome
criteria, with an OR of 1.9 (1.6–2.3) by Rome IV and 2.0
(1.6–2.5) for Rome III criteria in the combined 3-country
sample. Rome IV FC rates were significantly higher in the
youngest age group in the overall sample than in any of the
Figure 1. Distribution of IBS subtypes among individuals meeting Rome IV vs Rome III diagnostic criteria in the combined 3-
country population survey sample and in each of the countries.older groups. In contrast, that relative elevation of con-
stipation rate in the youngest age group was not seen in FC
diagnosed by Rome III criteria (see Table 3).
Functional diarrhea. Rome IV functional diarrhea had
an overall prevalence of 4.7% in the total study sample, but
the rate was significantly higher in Canada (5.6%) than in
the United Kingdom (3.8%), with the United States in the
middle and not different from either of the other countries.
The prevalence was highest among individuals in the age
group from 35 to 49 years, and the diarrhea prevalence in
that group was significantly higher than in younger adults
and those age 65 years and older. The sexes did not differ in
functional diarrhea rates (Table 3).
Rome III functional diarrhea had an overall prevalence
rate that was a mere one-fifth of the prevalence of that same
diagnosis by Rome IV criteria, or 0.9% for the combined 3-
country sample. This reflects the impact of the substantial
lowering of the frequency threshold of diarrhea stools
required for diagnosis in Rome IV vs Rome III; from 75% to
merely >25% of all stools. There were no significant dif-
ferences between age or sex groups in Rome III functional
diarrhea prevalence.Functional abdominal bloating/distention. In the
total study sample, 3.1% of individuals met diagnostic
criteria for functional bloating/distention. The prevalence
rate was significantly higher in Canada compared to the
United States, with the UK prevalence in the middle and not
different from either of the other countries. Bloating/
distention prevalence was substantially higher in women
than men, with OR of 2.8 (2.0–3.9), and lower in individuals
65 years and older compared with other age groups.
Unspecified bowel disorder. Criteria for unspecified
bowel disorder were met by 9.1% of individuals across the
3 countries in our sample. The prevalence was highest in
Canada and lowest in the UK. More women than men met
criteria for this diagnosis, with an OR of 1.3 (1.1–1.6) and
the rates were higher among individuals younger than 35
compared with older groups.
Opioid-induced constipation. Fewer individuals in
our study sample qualified for the new Rome IV OIC diag-
nosis compared with the other 5 Rome IV FBDs. The prev-
alence was 1.5% in the total sample, with all 3 countries
showing less than 2% prevalence. Women were more than
twice as likely as men to qualify for OIC, with an OR of 2.2
Figure 2. Comparison of the 3 different factors explaining lower Rome VI IBS prevalence compared with Rome III IBS in the
combined 3-country population survey sample (left side bars), as percentage of all people disqualified from Rome IV IBS: A,
Fewer people report abdominal “pain” than “discomfort or pain” at Rome III threshold (16.8%); B, fewer people meet stool-
associated criteria in Rome IV compared with Rome III (2.5%); and C, fewer people meet 1  week minimum than the 2 to
3 times/month pain threshold (80.7%). The pie graph shows the distribution of Rome IV FBD diagnoses for which the Rome III
IBS cases who failed Rome IV IBS criteria qualified instead.(1.4–3.5). Individuals in the age range from 35 to 49 had
higher OIC prevalence compared with both the youngest
and oldest age groups (Table 3).
Census-Adjusted Prevalence Estimates
Our national samples in this study were not entirely
equivalent in age distribution to those of the nations they were
drawn from, and this was likely to have some effect on the
prevalence estimates for each of the 6 diagnoses we evaluated.
To obtain more precise estimates of the national prevalence
rates of the bowel disorders, we used the latest census data for
each country to compute census weights for each participant
for age and sex. As can be seen by comparing the numbers in
Table 4 with those in Table 2, these census adjustments made
negligible differences in the prevalence figures overall and for
the individual countries, generally altering estimates for each
disorder by only a fraction of percent.
Impact of the FBDs on Quality of Life and GI
Health Care Seeking
To examine the subjective life impact of FBDs in the
general population, we examined whether they were asso-
ciated with impairment in the mental and physical di-
mensions of quality of life as measured with the SF-8
questionnaire. As seen in Figure 3, individuals with each of
the 6 disorders had significantly impaired quality of life
compared with people in our sample who did not qualify for
any FBD diagnosis. People who met Rome IV IBS criteria had
significantly poorer mental quality of life (SF-8 Mental
Component Score) than those with all the other boweldisorders. Individuals with OIC had the lowest physical
quality of life (SF-8 Physical Component Score), even lower
than those with IBS, who in turn had lower physical quality
of life than all other FBDs (Figure 3).
Overall, more than a third of individuals who met Rome IV
criteria for any FBD in our survey reported that they had con-
sulted a doctor about GI health problems in the past, and they
were twice as likely to have done so compared with people not
meetingFBDcriteria (36.1%vs17.5%;P< .0001). Thisdoubling
of likelihood of past GI health care consulting among FBD cases
was seen for bothmen (32.5%vs 15.6%;P< .0001) andwomen
(38.4% vs 20.4%; P < .0001) and in each of the 3 countries
(30.1%vs15.6%in theUnitedStates, 38.1%vs18.6%inCanada,
and 39.9% vs 18.4% in the United Kingdom; P < .0001 for all
comparisons). People meeting IBS criteria had a significantly
higher rate of GI consulting (61.3%) than those with any of the
other FBDs, whereas individuals with OIC had a higher GI
consultation rate (50.5%) than those with all FBDs except IBS.
Discussion
In this report, we provide a comprehensive picture of the
prevalence and demographic distribution of FBDs in the
national populations of 3 Western countries, using the
recently launched Rome IV criteria.1 Our findings show that
this class of functional GI disorders is very common, present
in 1 of every 4 adults.
We found that the rates of the bowel disorders are
generally similar among the countries we surveyed. Even
where differences were found between countries, the per-
centage differences were generally relatively modest
Table 4.Estimated Prevalence of Functional Bowel Disorders
Census-Adjusted for Sex and Age in the Combined
Three-Country Population Survey Sample and Each












Irritable bowel syndrome 4.6 4.8 4.7 4.4
Functional constipation 8.1 7.9 7.9 8.6
Functional diarrhea 4.7 5.2 5.3 3.6
Functional bloating/
distention
3.1 2.0 3.9 3.3
Opioid-induced
constipation
1.6 1.8 1.1 1.9
Unspecified bowel
disorder
9.1 10.0 9.6 7.5
Any bowel disorder 30.4 30.9 31.7 28.6
Rome III
Irritable bowel syndrome 9.2 8.8 9.7 9.8
Functional constipation 5.7 5.2 5.0 6.8
Functional diarrhea 0.8 0.9 0.9 0.6(Table 2). This suggests that our prevalence figures are
likely to be reasonably close approximations of true national
prevalence of FBDs as defined by Rome IV.
Perhaps the single most notable finding from our analyses
was that IBS rates are reduced by half when the disorder is
diagnosed by Rome IV rather than by Rome III criteria.1,4 The
fact that this halving of prevalence was seen in each of the
countries separately makes clear that it is a direct function of
the changed diagnostic criteria. Our analyses of the reasons
for this reduction in IBS rates in Rome IV provided useful
insights into the effects of changing individual aspects of the
IBS criteria. They indicated that the decision to raise the
minimum pain frequency threshold is the principal cause of
reduced IBS rates with Rome IV, whereas eliminating the
word “discomfort” from the pain criterion and changes in
criteria related to association between stools and pain
affected diagnostic rates only slightly. Recent retrospective
surveys of clinical samples of IBS patients fulfilling Rome III
criteria for the disorder highlight that the vast majority also
fulfill Rome IV criteria for IBS, hence meeting the higher fre-
quency threshold of abdominal pain required by the new
criteria.16,17 This indicates that the drop in prevalence rate
seen in our population-based study from using the new
version of the criteria is not likely to reduce IBS diagnoses
much in specialty clinics. However, data from a recent study
in China suggest that this could possibly differ between
Eastern and Western countries.18 Moreover, differences in
symptom clusters defining functional GI disorders between
Asia and Western countries have been proposed,19,20 high-
lighting the need to assess whether the findings from this
study are valid also in other parts of the world, including Asia.
Our findings regarding differences in IBS subtype distri-
bution in Rome IV vs Rome III are clinically important. Rome
IV subtyping of IBS reduces the large group of patients that
has been classified as IBS-M in Rome III, dividing half of thembetween IBS-D and IBS-C and thereby making both of those
other subtypes more prominent. This may be critically
important in the management of patients with IBS, as phar-
macologic treatment has offered much better options to date
for treating the latter 2 subtypes.21 The reasons for the
shrinkage of the IBS-M proportion in Rome IV are unclear, but
it could be due in part to Rome IV subtyping asking patients in
a multiple-choice fashion what kind of stool abnormality is
usual for them on days with abnormal stools. If patients
experience substantial difference between amounts of diar-
rhea and constipation, they might be prone to choose the
predominant one instead of answering “both,” even if both
types occur at higher than the required 25% threshold. Unlike
the Rome III subtyping, which is based on separate responses
about percent of diarrhea and constipation stools out of all
bowel movements, the Rome IV approach might thereby
possibly favor IBS-D and IBS-C over IBS-M.
Unlike the drop in IBS prevalence seen when Rome IV
criteria are used instead of Rome III, we found that the
newer criteria increase prevalence rate of functional diar-
rhea 5-fold (from 0.9% to 4.7% in the overall sample). This
large Rome IV boost in functional diarrhea rates is not
surprising, as the Rome IV criteria substantially lowered the
diagnostic threshold for diarrhea-type stools (>25% vs
75% of all stools in the past 3 months), and unlike Rome III
they do not disqualify patients from diagnosis who report
abdominal pain unless they meet IBS criteria.
We also found FC rates to be higher when Rome IV
criteria are applied than with Rome III. This is under-
standable given the large reduction in IBS diagnosis pro-
duced by Rome IV, as a portion of the individuals no longer
qualifying for IBS in Rome IV will instead classify as FC, as
seen in Figure 2. However, a surprising finding regarding FC
diagnosis was the fact that Rome IV FC rates were signifi-
cantly higher in the youngest age group (18–34 years)
compared with older groups. This is at odds with prior
research using earlier FC criteria, which found FC rates to be
highest in the oldest age groups.7,8 Furthermore, this
elevation of FC rates in the youngest age group was not seen
in our sample when Rome III FC criteria were applied.
Elevation in FC among the young does seem likely to have
something to do with Rome IV criteria rather than being a
statistical anomaly, however, because we found higher nu-
merical FC rates to be present in all 3 countries separately,
and in both sexes. We cannot explain this, nor the general
absence of the expected rise in constipation rates in the
oldest age groups in our samples. Future research studies,
such as the Rome Global Epidemiology Survey that has just
been concluded, will need to confirm or disconfirm these
unexpected constipation age effects observed in our study.
Overall, the change from Rome III to Rome IV results in
reduced prevalence of IBS and increased prevalence of FC
and functional diarrhea. The clinical implications of this shift
are unclear, as our findings are from the general population,
including large groups of individuals with FBD who have not
sought health care for their bowel symptoms, and findings
from existing retrospective and cross-sectional studies in
clinical populations have been mixed.16–18 However,
because some of the available pharmacological agents for
Figure 3. SF-8 quality of life scores of individuals with each of the 6 Rome IV FBDs in the 3-country survey sample (N ¼ 5931),
compared with individuals with no bowel disorder.FBDs are approved for individual disorders only,21 the shift
among diagnoses between Rome III and Rome IV may
jeopardize availability of approved drugs for a proportion of
individuals with FBD.
Our analyses revealed a significant impact of the FBDs on
quality of life and GI-related health care seeking. This is in
agreementwith numerous previous research studies.22–24 All 6
FBDs were associated with measurable impairment in both
physical functioning and mental well-being; however, IBS
stands out in our results as a diagnostic entity particularly
strongly associated with poor mental and physical functioning.
Similarly, individuals with all the FBDs showed significantly
greater tendency to have consulted doctors for GI problems
than individuals without such disorders, but IBS was more
strongly associated with GI consultation than any of the other
disorders.
The results on OIC presented here provide the first data
on the population-based presence of this new FBD. The
findings show that although it is less common than the other
FBDs, it is a health problem with significant adverse effects,
and seems to rival IBS in quality of life impact and GI health
care utilization. It is noteworthy that individuals meeting
OIC criteria reported even poorer physical quality of life
than those with IBS or any of the other FBDs; however, that
finding should probably be interpreted with caution, as theSF-8 measures only overall physical functioning. The
marked physical impairment it measures in individuals with
OIC could be related more to other health problems for
which they are taking opioids than bowel symptoms related
to the opioid use, implicating that quality of life reduction in
patients with OIC may be a multifaceted problem.25
The study of FBDs that we present here had some
notable strengths. One of these was the multinational
composition of the sample across English-speaking Western
countries that share many cultural and economic similar-
ities. It provided 3 independent side-by-side snapshots of
FBDs in similar Western world populations, diagnosed
based on the same questions answered by all respondents
in the same language. This eliminated much of the potential
confounding associated with divergent cultures, dissimilar
living conditions, and differences in languages.5 Equally
important, the 3 national samples were practically identical
in their sex and age group distribution by design, and each
had excellent nationwide subject distribution. All of this
enabled direct nation-to-nation prevalence comparisons
without confounding from any major differences in de-
mographic composition, language, or cultures. Additional
methodological strengths were the fact that survey partici-
pants were unaware of the GI focus of the survey when they
enrolled, and the multiple quality control methods that
prevented poor responses in the dataset, such as the built-in 
attention-check questions.
A limitation that our study shares with all cross-
sectional population surveys is the fact that because most 
of the respondents who met diagnostic criteria had never 
visited a doctor for GI health problems, the symptoms on 
which diagnoses were based were largely medically unin-
vestigated. Some individuals to whom we assigned an FBD 
diagnosis may therefore have had undiscovered organic 
disease causing their symptoms.
Another potential limitation of this study is that it used 
Internet-based surveying rather than more traditional epide-
miological survey methodology. However, as we know of no 
evidence to suggest that Internet survey-takers differ in their 
GI health status from other people with comparable de-
mographic characteristics, it seems unlikely that this would 
affect our FBD findings. In the highly developed countries we 
surveyed, 88% to 90% of all adults are Internet users26 and 
daily Internet use has become a normal way of life for most of 
the general population. For this reason, and because the de-
mographic parameters of our national samples, including age, 
sex, education, and geographic distribution, were all similar to 
those of the actual population of those countries, we believe 
that the samples we obtained are likely to be representative of 
the general populations of the countries we studied. However, 
it must be acknowledged that Internet surveying does exclude 
the small segment of the adult population who are unable to 
use the Internet, such as illiterate or cognitively impaired 
individuals and those living in remote areas without Internet 
service.
Finally, one more limitation of the study methodology 
was that the survey was conducted at a time when the Rome 
IV Diagnostic Questionnaire had not yet been published or 
translated. This restricted the surveying to English-speaking 
subjects, which in particular may have limited participation 
among native French speakers in Canada, as some of them 
are not fluent in English. The fact that our survey data were 
obtained exclusively from English-speaking individuals in 3 
Western nations with many cultural similarities means that 
the findings may not be generalizable to other language 
groups or cultural regions of the world.
In summary, the findings presented here offer the first 
comprehensive picture of Rome IV FBDs in the adult pop-
ulations in 3 English-speaking countries. They provide es-
timates of the prevalence of each disorder that are likely to 
be reliable based on their similarities between countries and 
application of census-based population weights, show the 
relative composition of this class of health problems as 
defined by the current diagnostic criteria, and confirm some 
of the patterns of age and sex differences in FBDs previously 
reported by others. Furthermore, these results provide il-
lustrations of the prevalence impact of changes introduced 
by Rome IV in IBS and functional diarrhea that may prove 
useful for guiding future development of the Rome criteria.Supplementary Material
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Supplementary Table 1.Demographic Comparison of







Sex (% female) 64.7 b 49.3
Age: Mean (SD) 39.5 (14.9)b 47.8 (30.5)
Percent of all subjects in
each age group:
18–34 y 9.0 89.0
35–49 y 6.9 93.1
50–64 y 4.4 95.6
65þ y 2.1 97.9
Years of education: mean (SD) 13.0 (3.7) 13.8 (3.8)
aInconsistent responders were those who deviated more than
one response scale step from their original response on 2 or
more of 3 Rome IV GI symptom frequency questions
repeated in the survey.
bSignificantly different from valid survey responders.
Supplementary Table 2.Distribution of the US Study
Subsample Across States, and
Comparison With the Distribution of







State % of total
US population
Alabama 27 1.4 1.5
Alaska 0 0 0.2
Arizona 48 2.5 2.1
Arkansas 20 1 0.9
California 249 12.8 12.3
Colorado 30 1.5 1.7
Connecticut 25 1.3 1.1
Delaware 7 0.4 0.3
District of Columbia 4 0.2 0.2
Florida 153 7.9 6.4
Georgia 73 3.7 3.2
Hawaii 4 0.2 0.5
Idaho 15 0.8 0.5
Illinois 84 4.3 4
Indiana 42 2.2 2.1
Iowa 20 1 1
Kansas 11 0.6 0.9
Kentucky 33 1.7 1.4
Louisiana 29 1.5 1.5
Maine 3 0.2 0.4
Maryland 40 2.1 1.9
Massachusetts 41 2.1 2.1
Michigan 55 2.8 3.1
Minnesota 31 1.6 1.7
Mississippi 14 0.7 0.9
Missouri 39 2 1.9
Montana 5 0.3 0.3
Nebraska 11 0.6 0.6
Nevada 21 1.1 0.9
New Hampshire 6 0.3 0.4
New Jersey 61 3.1 2.8
New Mexico 14 0.7 0.7
New York 120 6.2 6.2
North Carolina 58 3 3.2
North Dakota 1 0.1 0.2
Ohio 78 4 3.7
Oklahoma 14 0.7 1.2
Oregon 24 1.2 1.3
Pennsylvania 103 5.3 4
Rhode Island 4 0.2 0.3
South Carolina 26 1.3 1.5
South Dakota 8 0.4 0.3
Tennessee 30 1.5 2.1
Texas 157 8.1 8.6
Utah 8 0.4 0.9
Vermont 1 0.1 0.2
Virginia 44 2.3 2.6
Washington 22 1.1 2.3
West Virginia 7 0.4 0.6
Wisconsin 25 1.3 1.8
Wyoming 4 0.2 0.2
Supplementary Table 3.Distribution of the UK Study Subsample Across the 10 Government Regions, and Comparison With
the Distribution of the UK National Population (Office of UK National Statistics 2015 estimates)
Region UK sample, n UK sample, %
Region % of total
UK population
East of England 174 8.7 9.21
London 212 10.6 12.88
Midlands 310 15.5 16.31
North East Yorkshire & the Humber 273 13.7 12.42
North West 271 13.6 11.11
Northern Ireland 33 1.7 2.95
Scotland 164 8.2 8.37
South East 288 14.4 13.6
South West 159 8 8.33
Wales 109 5.5 4.83
Supplementary Table 4.Distribution of the Canadian Study Subsample Across Provinces and Territories, and Comparison








of total Canadian population
Alberta 210 10.6 11.7
British Columbia 347 17.5 13.08
Manitoba 113 5.7 3.63
New Brunswick 53 2.7 2.09
Newfoundland and Labrador 25 1.3 1.47
Nova Scotia 77 3.9 2.62
Ontario 910 45.8 38.5
Prince Edward Island 15 0.8 0.41
Quebec 171 8.6 23
Saskatchewan 65 3.3 3.17
Yukon 2 0.1 0.1
Northwest Territories 0 0 0.12
Nunavut 0 0 0.1
Supplementary Table 5.Distribution of the US Male and Female Subsamples Across Age Groups, and Comparison With




% of US male
sample




% of US female
sample
% of US female
18þ population
18–29 217 22.0 22.7 158 16.4 20.6
30–39 188 19.0 17.5 190 19.8 16.5
40–49 107 10.8 16.9 143 14.9 16.2
50–59 155 15.7 17.9 194 20.2 17.7
60–69 217 22.0 13.9 180 18.7 14.4
70þ 103 10.4 11.2 95 9.9 14.3
Supplementary Table 6.Distribution of the UK Male and Female Subsamples Across Age Groups, and Comparison With




% of UK male
sample




% of UK female
sample
% of UK female
18þ population
18–29 138 13.6 20.9 223 22.8 19.3
30–39 181 17.8 16.8 234 24.0 16.2
40–49 139 13.7 17.6 128 13.1 17.2
50–59 199 19.5 16.8 153 15.7 16.4
60–69 243 23.9 13.9 165 16.9 13.9
70þ 118 11.6 13.9 72 7.4 17.1
Supplementary Table 7.Distribution of the Canadian (CA) Male and Female Subsamples Across Age Groups, and










% of CA female
sample
% of CA female
18þ population
18–29 184 18.3 19.9 188 19.2 18.3
30–39 208 20.6 16.6 199 20.3 16.3
40–49 96 9.5 16.6 137 14.0 16.3
50–59 179 17.8 19.1 208 21.2 18.6
60–69 216 21.4 15.1 174 17.8 15.2
70þ 124 12.3 12.8 73 7.4 15.4
Supplementary Table 8.Distribution of Total Study Subject Sample From the 3 Countries Across Age Groups, Compared













adults 18þ y in the 3 countries
18–29 539 569 17.9 19.5 18.7 21.2
30–39 577 623 19.2 21.4 20.2 16.9
40–49 342 408 11.4 14.0 12.7 16.7
50–59 533 555 17.7 19.0 18.3 17.7
60–69 676 519 22.4 17.8 20.2 14.2
70þ 345 240 11.5 8.2 9.9 13.3
All ages 3013 2918
